<DOC>
	<DOCNO>NCT03043651</DOCNO>
	<brief_summary>This open-label study evaluate safety continue therapy oral treprostinil subject complete Study TDE-HF-301 . This study provide long-term , open-label data regard effect continue long-term oral treprostinil therapy treatment pulmonary hypertension ( PH ) associate heart failure preserve ejection fraction ( HFpEF ) . Subject visit occur Baseline , Weeks 6 , 12 , 18 , 24 , every 12 week thereafter either oral treprostinil become commercially available treat PH associate HFpEF study discontinue Sponsor .</brief_summary>
	<brief_title>Study Oral Treprostinil Subjects With Pulmonary Hypertension ( PH ) Associated With Heart Failure With Preserved Ejection Fraction ( HFpEF )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>The subject participate Study TDEHF301 , remain study drug , compliant study procedures assessment Study TDEHF301 , complete Week 24 study . Exclusion Criteria The subject pregnant lactating . The subject prematurely discontinue Study TDEHF301 reason . The subject develop concurrent illness condition Study TDE HF 301 , , opinion Investigator , would represent risk subject 's overall health enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>HFpEF</keyword>
	<keyword>6-Minute Walk Test</keyword>
	<keyword>Oral Treprostinil</keyword>
</DOC>